AARD (Aardvark Therapeutics) ROCE %: -92.82% (As of Mar. 2026)


AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $4.79
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics ROCE %?

Aardvark Therapeutics AARD -5.34% 12 ROCE % is -92.82% as of Mar. 2026. GuruFocus rates AARD with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aardvark Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -92.82%.

Aardvark Therapeutics  (NAS:AARD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aardvark Therapeutics ROCE % Related Terms

Aardvark Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Aardvark Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aardvark Therapeutics ROCE % Chart

Aardvark Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
-67.28 -52.56 -55.47 -70.00

Aardvark Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.45 -43.99 -54.54 -65.31 -92.82
AARD
12GF Score
Aardvark Therapeutics Inc AARD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics ROCE % Calculation

Aardvark Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-62.725/( ( (77.507 - 4.927) + (117.181 - 10.548) )/ 2 )
=-62.725/( (72.58+106.633)/ 2 )
=-62.725/89.6065
=-70.00 %

Aardvark Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-89.856/( ( (117.181 - 10.548) + (98.59 - 11.604) )/ 2 )
=-89.856/( ( 106.633 + 86.986 )/ 2 )
=-89.856/96.8095
=-92.82 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -92.82% mean?
Aardvark Therapeutics (AARD) has a ROCE % of -92.82% as of Mar. 2026.
Is Aardvark Therapeutics' ROCE % too high?
Aardvark Therapeutics' current ROCE % is -92.82%. Overall, Aardvark Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aardvark Therapeutics' ROCE % compare to TELO and OKYO?
Aardvark Therapeutics' ROCE % of -92.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Aardvark Therapeutics's current ROCE % is -92.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aardvark Therapeutics stock overvalued right now?
Aardvark Therapeutics (AARD) has a current ROCE % of -92.82%. The current ROCE % is -92.82%. Aardvark Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Aardvark Therapeutics (AARD), the current ROCE % is -92.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price